BOSTON, September 3, 2020 (GLOBE NEWSWIRE) – Inozyme Pharma, Inc.(Nasdaq: INZY), a biopharmaceutical of rare diseases that introduces new treatments for the remedy of abnormal mineralization diseases affecting the vascular system, soft tissues and skeleton, launched today its monetary effects for the quarter-final period ended June 30, 2020 and presented recent events of its business.
Recent corporate highlights
Second Quarter 2020 Financial Results
About Inozyme Pharma
Inozyme Pharma is a biopharmaceutical company of rare diseases that presents new cures for the remedy of abnormal mineralization diseases that affect the vascular system, soft tissues and skeleton. Through our in-depth knowledge of the biological pathways involved in mineralization, we continue to potentially expand first cure to address the underlying reasons for these debilitating diseases.It is well established that two genes, ENPP1 and ABCC6, play a key role in a critical mineralization path and that the defects of those genes lead to abnormal mineralization.about the progression of a new cure to treat rare genetic diseases of ENPP1 and ABCC6 deficiencies.
Caution related to forward-looking statements
Statements included in this press release regarding expectations, plans and long-term prospects, as well as any other statements relating to matters other than old facts, may constitute “forward-looking statements” within the meaning of the Securities Litigation Reform Act. Private . 1995. These statements include, but are not limited to, statements regarding the initiation and timing of our long-term clinical trials, progression studies and programs, the availability of knowledge from preclinical studies and clinical trials, and the era in We believe that our money and its money equivalents will be sufficient to finance our operating expenses. The words “anticipate”, “believe”, “continue”, “can also simply”, “estimate”, “expect”, “pretend”, “can”, “plan”, “prospective”, “anticipate” Matrix “Plan “,” deserves “,” objective “,” will “,” would “and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements include those identifying words. Any forward-looking statement is discovered in the existing expectations of management with respect to long-term occasions and is subject to a number of dangers and uncertainties that may also cause the actual effects to differ adversely and dramatically from those stated or implied through of prospects. statements. These hazards and uncertainties include, but are not limited to, hazards relevant to the Company’s ability to clinically block effectively with respect to its planned phase 1/2 clinical trial of INZ-701 for ENPP1 deficiency. ; download and maintain mandatory approvals from the FDA and other regulatory authorities; continue to advance your product applicants in preclinical studies and clinical trials; reflect in future clinical trials the positive effects discovered in preclinical studies and entry-level clinical trials of its product applicants; advance the progression of your product applicants as scheduled in planned, long-term clinical trials; download, maintain and protect the rights of intellectual assets similar to those of your product applicants; manage expenses; and raising the really extensive additional capital needed to achieve your business goals. For a discussion of other hazards and uncertainties, and other vital factors, any of which may also cause the Company’s actual effects to differ from those involved in the forward-looking statements, please see the “Risk Factors” section, as well as discussions of potential hazards, uncertainties and other curtain factors, in the company’s recent top filings with the Securities and Exchange Commission and Exreplace. In addition, the forward-looking statements included in this press release constitute the Company’s outlook as of the date hereof and are not to be construed as the Company’s outlook at any date close to the date hereof. The Company anticipates that upcoming occasions and progressions will cause a replacement in the opinion of the Company. However, even though the company may decide to update those forward-looking statements at some point in the long term, the company expressly disclaims any legal responsibility to do so.
Condensed Consolidated Balance Sheet Data (Unaudited)
(thousands)
contacts
Investors:
Solebury Mike Biega Trout (617) 221 9660 [email protected]
SmithSolve Alex Van Rees (973) 442-1555 ext. 111 [email protected]